These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 21864598

  • 1. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.
    Forbes CJ, Lowry D, Geer L, Veazey RS, Shattock RJ, Klasse PJ, Mitchnick M, Goldman L, Doyle LA, Muldoon BC, Woolfson AD, Moore JP, Malcolm RK.
    J Control Release; 2011 Dec 10; 156(2):161-9. PubMed ID: 21864598
    [Abstract] [Full Text] [Related]

  • 2. Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.
    Forbes CJ, McCoy CF, Murphy DJ, Woolfson AD, Moore JP, Evans A, Shattock RJ, Malcolm RK.
    J Pharm Sci; 2014 May 10; 103(5):1422-32. PubMed ID: 24585370
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques.
    Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Klasse PJ, Moore JP.
    J Antimicrob Chemother; 2013 Mar 10; 68(3):678-83. PubMed ID: 23111849
    [Abstract] [Full Text] [Related]

  • 4. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.
    Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJ, Doyle LA, Rasmussen KK, Goldman L, Ketas TJ, Moore JP.
    Antimicrob Agents Chemother; 2012 May 10; 56(5):2251-8. PubMed ID: 22330914
    [Abstract] [Full Text] [Related]

  • 5. Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV.
    Ball C, Woodrow KA.
    Antimicrob Agents Chemother; 2014 Aug 10; 58(8):4855-65. PubMed ID: 24913168
    [Abstract] [Full Text] [Related]

  • 6. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.
    Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP.
    J Infect Dis; 2010 Sep 01; 202(5):739-44. PubMed ID: 20629537
    [Abstract] [Full Text] [Related]

  • 7. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action.
    Fetherston SM, Boyd P, McCoy CF, McBride MC, Edwards KL, Ampofo S, Malcolm RK.
    Eur J Pharm Sci; 2013 Feb 14; 48(3):406-15. PubMed ID: 23266465
    [Abstract] [Full Text] [Related]

  • 8. Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
    Fox J, Tiraboschi JM, Herrera C, Else L, Egan D, Dickinson L, Jackson A, Olejniczak N, Back D, Khoo S, Shattock R, Boffito M.
    J Acquir Immune Defic Syndr; 2016 Nov 01; 73(3):252-257. PubMed ID: 27727157
    [Abstract] [Full Text] [Related]

  • 9. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
    Neff CP, Kurisu T, Ndolo T, Fox K, Akkina R.
    PLoS One; 2011 Nov 01; 6(6):e20209. PubMed ID: 21673796
    [Abstract] [Full Text] [Related]

  • 10. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.
    Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP.
    Proc Natl Acad Sci U S A; 2012 May 29; 109(22):8694-8. PubMed ID: 22586094
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.
    Dezzutti CS, Yandura S, Wang L, Moncla B, Teeple EA, Devlin B, Nuttall J, Brown ER, Rohan LC.
    Pharm Res; 2015 Nov 29; 32(11):3768-81. PubMed ID: 26078001
    [Abstract] [Full Text] [Related]

  • 12. Interactions between alcohol and the HIV entry inhibitor Maraviroc.
    Gruber VA, Rainey PM, Lum PJ, Beatty GW, Aweeka FT, McCance-Katz EF.
    J Int Assoc Provid AIDS Care; 2013 Nov 29; 12(6):375-7. PubMed ID: 23881910
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.
    McBride JW, Dias N, Cameron D, Offord RE, Hartley O, Boyd P, Kett VL, Malcolm RK.
    Antimicrob Agents Chemother; 2017 Oct 29; 61(10):. PubMed ID: 28784672
    [Abstract] [Full Text] [Related]

  • 14. Anti-HIV agents. Maraviroc--absorption and drug-interaction issues.
    TreatmentUpdate; 2007 Oct 29; 19(3):5. PubMed ID: 17571441
    [No Abstract] [Full Text] [Related]

  • 15. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1.
    Grammen C, Ariën KK, Venkatraj M, Joossens J, Van der Veken P, Heeres J, Lewi PJ, Haenen S, Augustyns K, Vanham G, Augustijns P, Brouwers J.
    Antiviral Res; 2014 Jan 29; 101():113-21. PubMed ID: 24269474
    [Abstract] [Full Text] [Related]

  • 16. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
    Moss JA, Butkyavichene I, Churchman SA, Gunawardana M, Fanter R, Miller CS, Yang F, Easley JT, Marzinke MA, Hendrix CW, Smith TJ, Baum MM.
    Antimicrob Agents Chemother; 2016 Jun 29; 60(6):3759-66. PubMed ID: 27067321
    [Abstract] [Full Text] [Related]

  • 17. SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses.
    Tsibris AM, Pal U, Schure AL, Veazey RS, Kunstman KJ, Henrich TJ, Klasse PJ, Wolinsky SM, Kuritzkes DR, Moore JP.
    PLoS One; 2011 Jun 29; 6(12):e28047. PubMed ID: 22164225
    [Abstract] [Full Text] [Related]

  • 18. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
    Veselinovic M, Yang KH, LeCureux J, Sykes C, Remling-Mulder L, Kashuba ADM, Akkina R.
    Virology; 2014 Sep 29; 464-465():253-263. PubMed ID: 25105490
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial.
    Dezzutti CS, Richardson-Harman N, Rohan LC, Marzinke MA, Hoesley CJ, Panther L, Johnson S, Nuttall JP, Nel A, Chen BA, Microbicide Trials Network, MTN-013/IPM 026 Protocol Team.
    Medicine (Baltimore); 2016 Jul 29; 95(28):e4174. PubMed ID: 27428211
    [Abstract] [Full Text] [Related]

  • 20. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.
    Garg S, Goldman D, Krumme M, Rohan LC, Smoot S, Friend DR.
    Antiviral Res; 2010 Dec 29; 88 Suppl 1():S19-29. PubMed ID: 21109064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.